Home » Stocks » Hologic

Hologic, Inc. (HOLX)

Stock Price: $68.12 USD 0.13 (0.19%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 17.64B
Revenue (ttm) 3.30B
Net Income (ttm) 496.80M
Shares Out 258.98M
EPS (ttm) 1.87
PE Ratio 36.43
Forward PE 19.61
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $68.12
Previous Close $67.99
Change ($) 0.13
Change (%) 0.19%
Day's Open 67.54
Day's Range 67.42 - 68.77
Day's Volume 1,868,396
52-Week Range 26.49 - 73.63

More Stats

Market Cap 17.64B
Enterprise Value 20.21B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 258.98M
Float 256.70M
EPS (basic) 1.88
EPS (diluted) 1.87
FCF / Share 2.20
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.75%
FCF Yield 3.25%
Payout Ratio n/a
Shares Short 4.69M
Short Ratio 1.36
Short % of Float 1.61%
Beta 1.52
PE Ratio 36.43
Forward PE 19.61
P/FCF Ratio 30.80
PS Ratio 5.35
PB Ratio 7.81
Revenue 3.30B
Operating Income 385.70M
Net Income 496.80M
Free Cash Flow 572.80M
Net Cash -2.57B
Net Cash / Share -9.93
Gross Margin 62.97%
Operating Margin 11.70%
Profit Margin 15.10%
FCF Margin 17.38%
ROA 6.25%
ROE 22.05%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (18)

Buy 12
Overweight 1
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$77.21*
(13.34% upside)
Low
68.0
Current: $68.12
High
84.0
Target: 77.21
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3,3673,2183,0592,8332,7052,5312,4922,0031,7891,680
Revenue Growth4.64%5.2%7.98%4.72%6.89%1.54%24.45%11.92%6.54%-
Gross Profit1,1711,6971,6211,5631,4331,2461,161994923737
Operating Income-124-238471549455280-89515236669.94
Net Income-204-11175633113217.30-1,173-73.60157-62.81
Shares Outstanding269275280280281275269264261259
Earnings Per Share-0.76-0.402.641.160.450.06-4.36-0.280.59-0.24
EPS Growth--127.59%157.78%650%-----
Operating Cash Flow6507338.30798797508494370456457
Capital Expenditures-114-106-108-94.50-89.40-80.20-90.10-78.70-55.66-46.66
Free Cash Flow536627-99.30704707428404292400410
Cash & Equivalents602667541548493742829566713517
Total Debt3,0763,3273,3473,3453,6124,2684,8065,0361,4891,448
Net Cash / Debt-2,474-2,660-2,807-2,797-3,120-3,526-3,977-4,469-776-932
Assets6,4427,2317,9807,3177,6438,4159,00110,4776,0095,626
Liabilities4,3264,8025,1955,1745,5636,3527,0597,5163,0722,927
Book Value2,1162,4292,7852,1432,0792,0631,9422,9612,9372,699
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Hologic, Inc.
Country United States
Employees 6,478
CEO Stephen P. MacMillan

Stock Information

Ticker Symbol HOLX
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: HOLX
IPO Date June 21, 1990

Description

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, surgical products, and light-based aesthetic and medical treatment systems for women in the United States and internationally. The company offers Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for acute respiratory ailments. It also provides breast imaging and analytics, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company offers aesthetic treatment systems, as well as TempSure, a radio frequency energy-sourced platform, which offers non-surgical and surgical aesthetic treatments and procedures. Further, it offers NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Additionally, the company offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.